Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

The Pharma Data

OCTOBER 19, 2020

.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. among adults 65 years of age or older.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2021

The first global authorization of molnupiravir is a major achievement in Merck’s singular heritage of bringing forward advance drugs and vaccines to address the world’s topmost health challenges. As an oral remedial, molnupiravir offers an important addition to the vaccines and drugs stationed so far to fight the COVID-19 epidemic,” saidDr.

Licensing 52

Licensing Licensing Vaccine Laboratories 52

The Pharma Data

SEPTEMBER 1, 2021

Participants are not eligible for the trial if they have received the first dose of a COVID-19 vaccine more than seven days prior to enrollment, have previously had COVID-19 or are showing any signs or symptoms of COVID-19. in collaboration with Ridgeback Biotherapeutics. About Ridgeback Biotherapeutics.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

The Pharma Data

OCTOBER 26, 2021

Li, administrative vice chairman and chairman, Merck Research Laboratories. “ Li, administrative vice chairman and chairman, Merck Research Laboratories. “ Food and Drug Administration (FDA), and is laboriously working to submit operations to other nonsupervisory agencies worldwide.

Treatment 52

Treatment Government Vaccine Research Laboratories 52

The Pharma Data

JUNE 7, 2022

Li, president, Merck Research Laboratories. Since licensed by Ridgeback, all funds used for the development of LAGEVRIO have been provided by Merck and Ridgeback. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. About Ridgeback Biotherapeutics.

Hospitals 40

Hospitals Research Laboratories Treatment Disease 40

The Pharma Data

FEBRUARY 12, 2022

Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories. Lilly has licensed and developed bebtelovimab after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. About BLAZE-4.

Treatment 40

Treatment Hospitals FDA Clinical Trials 40